查看购物车
  • Traditional Chinese
  • Japanese
  • Korean
全球脓毒症诊断市场：市场趋势及至2031年预测
市场调查报告书
商品编码
1868995

全球脓毒症诊断市场：市场趋势及至2031年预测

Worldwide Sepsis Diagnostic Products: Market Insights and Forecasts to 2031
出版日期: | 出版商: Kalorama Information | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

败血症仍然是现代医学面临的最迫切、成本最高的挑战之一。败血症的特征是机体对感染产生危及生命的免疫反应，每年影响全球约2,700万人，造成500万人死亡。光是在美国，每年就有约200万例脓毒症病例和27万例死亡。早期发现对于提高存活率至关重要，但由于每位患者的症状复杂多样，早期发现仍然极具挑战性。败血症是美国医院治疗费用最高的疾病，因此，对准确、快速且易于取得的诊断工具的需求从未如此迫切。

Kalorama Information发布的 "全球脓毒症诊断市场－市场趋势及至2031年预测" 报告对全球脓毒症诊断市场进行了全面评估，涵盖体外诊断（IVD）、分子诊断及相关检测方法。本报告提供截至 2031 年的全球销售数据和预测，涵盖所有主要地区以及美国、中国、印度和日本等关键市场。

全面的研究方法和可靠的数据

市场规模估算以目前美元为单位，代表临床实验室、医院和诊所最终用户在败血症诊断产品和耗材上的总支出。本分析不包括用于执行这些测试的诊断设备和系统的成本，以确保报告数据准确反映产品使用趋势。所有货币换算均使用购买力平价指数，以确保各地区的一致性。

本研究基于广泛的一手和二手研究，包括对行业专家和製造商的访谈、政府和行业数据以及市场领导者的最新公开披露资讯。此外，还参考了部分 Kalorama 出版物和行业报告，以验证研究结果并识别新兴趋势。

本报告的重要性

随着全球医疗保健系统将早期检测、成本控制和患者预后放在首位，本报告提供了评估脓毒症诊断市场格局所需的关键市场情报。它为以下方面提供了数据驱动的基础：

  • 主要地区的市场规模估算与预测
  • 诊断开发商之间的竞争基准分析
  • 投资、合作与产品扩张的策略规划

随着败血症带来的临床和经济负担不断推动创新， "全球脓毒症诊断产品市场－市场趋势和预测（至2031年）" 报告帮助决策者获得重要洞察，并驾驭不断发展的全球医疗诊断产业。

目录

第一章：摘要整理

第二章：引言

  • 脓毒症概述
    • 诊断工具
    • 应用范围
  • 专业指南与定义
    • 全身性发炎反应症候群 (SIRS) 标准和败血症 - 1
    • 败血症 - 2
    • 败血症 - 3
    • 战胜败血症运动
    • 序贯器官衰竭评估 (SOFA) 和定量序列器官衰竭评估 (qSOFA) 评分
  • 市场考量

第三章 生物标记

  • 乳酸、C 反应蛋白 (CRP)、降钙素原 (PCT) 和其他生物标记
  • 概述
  • 脓毒症中使用的生物标记
    • 降钙素原 (PCT)
  • C反应蛋白 (CRP)
    • 乳酸
    • 细胞因子
    • RNA、mRNA 和 microRNA (miRNA)
    • 肾上腺髓质素原 (ProADM)
    • D-二聚体
  • 多标记检测方法
    • 主要公司和平台

第四章 分子检测与质谱分析

  • 病原体鑑定和表征
  • 多重分子侦测
    • 脓毒症中使用的多重分子检测
    • 质谱分析
    • 微生物鑑定与药敏试验产品
    • 个人化医疗

第五章：市面上及研发中主要的败血症相关产品

  • 诊断产品及新兴技术
  • 产品开发问题
  • 人工智慧和机器学习在败血症诊断的应用

第六章：败血症诊断市场预测

  • 败血症诊断市场概况
  • 败血症生物标记市场
  • 败血症分子检测与质谱市场
  • 主要参与者的竞争格局

第7章 企业简介

  • 市场动态
  • ABBOTT
  • ABIONIC
  • ACCELERATE DIAGNOSTICS
  • BAYESIAN HEALTH
  • BECTON, DICKINSON AND COMPANY (BD)
  • BIOMERIEUX
  • BRUKER CORPORATION
  • CELLECTRIC BIOSCIENCES
  • CUBE DX
  • CYTOVALE
  • DANAHER CORPORATION
  • DIASORIN
  • FLUILUX
  • GENMARK DIAGNOSTICS/HOLOGIC
  • GRADIENTECH
  • HELIXBIND
  • IMMUNEXPRESS
  • KARIUS
  • INFLAMMATIX
  • MEMED
  • MOLZYM GMBH
  • MOMENTUM BIOSCIENCES
  • NOVUS DIAGNOSTICS
  • OCEAN DX
  • PRENOSIS
  • Q-LINEA
  • QIAGEN
  • QUIDELORTHO
  • RADIOMETER
  • ROCHE
  • SEEGENE
  • SIEMENS HEALTHINEERS
  • T2 BIOSYSTEMS
  • TEMPUS
  • THERMO FISHER SCIENTIFIC
简介目录
Product Code: 25-077KA

Sepsis remains one of the most urgent and costly challenges in modern healthcare. Characterized by a life-threatening immune response to infection, sepsis affects an estimated 27 million people and causes 5 million deaths worldwide each year, including approximately 2 million cases and 270,000 deaths in the United States alone. Early detection is critical to survival, yet remains difficult due to the condition's complex and variable presentation across patients. As the most expensive condition treated in U.S. hospitals, the need for accurate, rapid, and accessible diagnostic tools has never been greater.

Kalorama Information's "Worldwide Sepsis Diagnostic Products: Market Insights and Forecasts to 2031" delivers a comprehensive assessment of the worldwide market for sepsis diagnostic products, including in vitro diagnostics (IVD), molecular diagnostics, and related testing approaches. The report provides global sales data and projections through 2031 for all major world regions and for key individual markets-the United States, China, India, and Japan.

Comprehensive Methodology and Reliable Data

Market estimates are presented in current U.S. dollars, representing total end-user spending on sepsis diagnostic products and consumables by clinical laboratories, hospitals, and physicians' offices. The analysis excludes the cost of diagnostic instruments and systems implementing these tests, ensuring that reported figures specifically reflect product utilization trends. All currency conversions were made using purchasing power indices for consistency across regions.

The study is built upon extensive primary and secondary research, including interviews with industry experts and manufacturers, government and trade data, and the latest public filings from market leaders. Selected Kalorama publications and industry reports were also leveraged to validate findings and identify evolving trends.

Why This Report Matters

With healthcare systems worldwide prioritizing early detection, cost containment, and patient outcomes, this report provides the critical market intelligence needed to evaluate the sepsis diagnostics landscape. It offers a data-driven foundation for:

  • Market sizing and forecasting across key geographies
  • Competitive benchmarking among diagnostic developers
  • Strategic planning for investment, partnerships, and product expansion

As the clinical and economic burden of sepsis continues to drive innovation, "Worldwide Sepsis Diagnostic Products: Market Insights and Forecasts to 2031" equips decision-makers with the insights necessary to navigate a growing and essential area of global healthcare diagnostics.

TABLE OF CONTENTS

CHAPTER 1: EXECUTIVE SUMMARY

  • OVERVIEW
  • HIGHLIGHTS
    • Diagnostic Approaches and Technologies
    • Market Size and Competition
    • 3 Key Takeaways from This Report
  • SCOPE AND METHODOLOGY
    • Methodology
    • Sources of Information
  • ABOUT KALORAMA INFORMATION

CHAPTER 2: INTRODUCTION

  • SEPSIS OVERVIEW
    • Diagnostic Tools
    • Scope of Use
  • PROFESSIONAL GUIDELINES AND DEFINITIONS
    • SIRS Criteria and Sepsis-1
    • Sepsis-2
    • Sepsis-3
    • Surviving Sepsis Campaign
    • SOFA and qSOFA Scores
  • MARKET CONSIDERATIONS
    • Table 2-1: Total Global Market for Sepsis Diagnostics, 2022-2031 ($ million) [Biomarkers, Mass Spectrometry (MS), Molecular Assays]
    • Figure 2-1: Total Global Market for Sepsis Diagnostics, 2022-2031 ($ million) [Biomarkers, Mass Spectrometry (MS), Molecular Assays]

CHAPTER 3: BIOMARKERS

  • Table 3-1: Top Biomarkers Used in Sepsis, 2025
  • Lactate, C-Reactive Protein (CRP), Procalcitonin (PCT) and Other Biomarkers
  • Overview
    • Figure 3-1: Global Market Share of Biomarkers Used in Sepsis Diagnosis, by Test Volume, 2025 (%) [C-Reactive Protein (CRP), Lactate, Procalcitonin (PCT) and Others]
    • Figure 3-2: Global Market Share of Biomarkers Used in Sepsis Diagnosis, by Sales Revenues, 2025 (%) [C-Reactive Protein (CRP), Lactate, Procalcitonin (PCT) and Others]
  • BIOMARKERS USED FOR SEPSIS
    • Procalcitonin (PCT)
  • C-Reactive Protein (CRP)
    • Lactate
    • Cytokines
    • RNA, mRNA, microRNA (miRNA)
    • Proadrenomedullin (ProADM)
    • D-Dimer
  • MULTI-MARKER APPROACHES
    • Key Companies and Platforms

CHAPTER 4: MOLECULAR ASSAYS AND MASS SPECTROMETRY

  • PATHOGEN IDENTIFICATION AND CHARACTERIZATION
  • MULTIPLEX MOLECULAR ASSAYS
    • Multiplex Molecular Assays Used for Sepsis
      • Table 4-1: Multiplex Molecular Assays Used for Sepsis, 2025
    • Mass Spectrometry
    • Products for Microbe Identification and AST
      • Table 4-2: Selected Mass Spectrometry Products Used for Microbial ID and AST, 2025
      • Table 4-3: Systems and Products for Bacterial Culture, Staining, Incubation, 2025
    • Personalized Medicine

CHAPTER 5: MAJOR SEPSIS-RELATED PRODUCTS ON THE MARKET AND UNDER DEVELOPMENT

  • DIAGNOSTIC PRODUCTS AND EMERGING TECHNOLOGIES
    • Table 5-1: Sepsis Diagnostic Products on the Market, 2025
  • PRODUCT DEVELOPMENT ISSUES
    • The Challenge in Modern Sepsis Management
    • The Financial Incentive vs. The Adoption Hurdle
    • The Chasm Between Innovation and Practice
    • The Verification and Liability Problem
    • Current Status
  • ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING IN SEPSIS DIAGNOSIS
    • Applications of AI/ML in Sepsis Diagnosis
    • Currently Available AI/ML Products for Sepsis Diagnosis
    • AI/ML Products Under Development and Emerging Trends
    • Future AI/ML Systems Are Integrating Diverse Data Types Beyond Standard EHRs
    • Challenges to Adoption and Performance
    • Future Trends

CHAPTER 6: SEPSIS DIAGNOSTICS MARKET ESTIMATES

  • Total Sepsis Diagnostics Market
    • Table 6-1: Total Global Market for Sepsis Diagnostics, 2022-2031 ($ million) [Biomarkers, Mass Spectrometry (MS), Molecular Assays]
    • Figure 6-1: Total Global Market for Sepsis Diagnostics, 2022-2031 ($ million) [Biomarkers, Mass Spectrometry (MS), Molecular Assays]
    • Figure 6-2: Total Global Market Share for Sepsis Diagnostics, 2025 vs. 2031 (%) [Biomarkers, Mass Spectrometry (MS), Molecular Assays]
    • Table 6-2: Global Market for Sepsis Diagnostics, by Region, 2022-2031 ($ million) [Africa/Middle East, Asia/Pacific (China, Japan, Other), Central/South America, Eastern Europe, North America (Canada/Mexico, United States), Western Europe]
    • Figure 6-3: Global Market for Sepsis Diagnostics, by Region, 2022-2031 ($ million) [Africa/Middle East, Asia/Pacific (China, Japan, Other), Central/South America, Eastern Europe, North America (Canada/Mexico, United States), Western Europe]
    • Figure 6-4: Global Market for Sepsis Diagnostics, Share by Region, 2025 vs. 2031 (%) [Africa/Middle East, Asia/Pacific (China, Japan, Other), Central/South America, Eastern Europe, North America (Canada/Mexico, United States), Western Europe]
  • Sepsis Biomarker Market
    • Table 6-3: Total Market for Sepsis Biomarkers, 2022-2031 ($ million) [Lab Immunoassay Tests, Rapid Immunoassay Tests]
    • Figure 6-5: Global Market for Sepsis Biomarkers, 2022-2031 ($ million) [Lab Immunoassay Tests, Rapid Immunoassay Tests]
    • Table 6-4: Global Market for Sepsis Biomarkers, by Region, 2022-2031 ($ million) [Africa/Middle East, Asia/Pacific (China, Japan, Other), Central/South America, Eastern Europe, North America (Canada/Mexico, United States), Western Europe]
    • Figure 6-6: Global Market for Sepsis Biomarkers, Share by Region, 2025 vs. 2031 (%) [Africa/Middle East, Asia/Pacific (China, Japan, Other), Central/South America, Eastern Europe, North America (Canada/Mexico, United States), Western Europe]
  • Market for Sepsis Molecular Assays and Mass Spectrometry
    • Table 6-5: Total Market for Sepsis Molecular Assays and Mass Spectrometry (MS) Tests, 2022-2031 ($ million)
    • Figure 6-7: Global Market for Sepsis Molecular Assays and Mass Spectrometry (MS) Tests, 2022-2031 ($ million)
    • Table 6-6: Global Market for Sepsis Molecular Assays and Mass Spectrometry (MS) Tests, by Region, 2022-2031 ($ million) [Africa/Middle East, Asia/Pacific (China, Japan, Other), Central/South America, Eastern Europe, North America (Canada/Mexico, United States), Western Europe]
    • Figure 6-8: Global Market for Sepsis Molecular Assays and Mass Spectrometry (MS) Tests, by Region, 2022-2031 ($ million) [Africa/Middle East, Asia/Pacific (China, Japan, Other), Central/South America, Eastern Europe, North America (Canada/Mexico, United States), Western Europe]
    • Figure 6-9: Global Market for Sepsis Molecular Assays and Mass Spectrometry (MS) Tests, by Region, 2025 vs. 2031 (%) [Africa/Middle East, Asia/Pacific (China, Japan, Other), Central/South America, Eastern Europe, North America (Canada/Mexico, United States), Western Europe]
  • Competitive Positions of the Major Players
    • Table 6-7: Leading Providers of Sepsis Diagnostic Products, by 2025 Sales ($ million) and Share (%)
    • Figure 6-10: Leading Providers of Sepsis Diagnostic Products, by Sales, 2025 ($ million)
    • Figure 6-11: Leading Providers of Sepsis Diagnostic Products, by Share, 2025 (%)
  • Market Leader Discussion

CHAPTER 7: COMPANY PROFILES

  • MARKET DYNAMICS
    • Inactive Companies and Products
    • Companies No Longer Focused on Sepsis Diagnostics
    • Companies Currently Active in the Sepsis Diagnostics Market
  • ABBOTT
    • Immunoassay Biomarkers
    • Molecular Diagnostics
    • Point-of-Care (POC) Solutions
    • Microbiology and Culture Systems
  • ABIONIC
    • abioSCOPE-R Platform and PSP Test
    • Pancreatic Stone Protein (PSP) as a Sepsis Biomarker
    • Testing Process and Interpretation
    • Clinical Benefits of PSP Detection
    • Limitations and Future Outlook
  • ACCELERATE DIAGNOSTICS
    • Core Technologies for Sepsis Management
    • Accelerate Pheno-R System
    • Accelerate Arc(TM) System
    • Future Innovation: Accelerate WAVE(TM) System
    • Strategic Impact on Sepsis Care
  • BAYESIAN HEALTH
    • Sepsis Detection with TREWS
    • Workflow Integration and Explainability
    • Clinical Validation and Impact
    • Challenges and Future Outlook
    • Broader Applications
  • BECTON, DICKINSON AND COMPANY (BD)
    • Blood Culture
    • Mass Spectrometry
  • BIOMERIEUX
    • Traditional Microbiology
    • Biomarkers for Sepsis
    • Blood Culture Systems
    • Immunoassays
    • Mass Spectrometry
  • BRUKER CORPORATION
    • Mass Spectrometry
    • Molecular Diagnostics
    • Strategic Acquisitions
  • CELLECTRIC BIOSCIENCES
    • Benefits for Sepsis Diagnosis and Management
    • Limitations and Challenges
  • CUBE DX
    • Core Technology and Applications
    • Technology Platform: hybcell
    • Benefits for Sepsis Management
    • Limitations and Considerations
  • CYTOVALE
    • IntelliSep: Technology Overview
    • Risk Stratification Bands
    • Clinical Impact and Benefits
    • Limitations and Considerations
  • DANAHER CORPORATION
    • Cepheid
    • Integrated Strategy
  • DIASORIN
    • Molecular Diagnostics Expansion
  • FLUILUX
    • Technology Overview
    • Clinical Impact on Sepsis Management
    • Limitations and Considerations
  • GENMARK DIAGNOSTICS/HOLOGIC
  • GRADIENTECH
  • HELIXBIND
  • IMMUNEXPRESS
    • SeptiCyte RAPID
    • Next Generation Products
  • KARIUS
  • INFLAMMATIX
    • TriVerity(TM)
    • Research
  • MEMED
    • MeMed BV
    • MeMed Severity
  • MOLZYM GMBH
    • MolYsis Technology
    • Diagnostic Products
    • Clinical Impact and Considerations
  • MOMENTUM BIOSCIENCES
  • NOVUS DIAGNOSTICS
  • OCEAN DX
  • PRENOSIS
  • Q-LINEA
  • QIAGEN
    • QIAstat-Dx
    • Sample Preparation Technologies
    • Digital PCR (dPCR)
    • Antimicrobial Resistance (AMR) Research Solutions
  • QUIDELORTHO
    • VITROS Sepsis Assay Menu
    • Point-of-Care (POC) Testing Solutions
    • Benefits in Sepsis Management
    • Limitations and Considerations
  • RADIOMETER
    • Blood Gas Analysis
    • Immunoassays
    • Integrated Solutions and Clinical Intelligence
  • ROCHE
    • Biomarkers
    • Molecular Assays
    • Point-of-Care and Critical Care Solutions
    • Digital and Integrated Solutions
  • SEEGENE
    • Magicplex(TM) Sepsis Real-time Test
    • Underlying Technology
    • Clinical Benefits
    • Limitations
  • SIEMENS HEALTHINEERS
  • T2 BIOSYSTEMS
    • The T2Dx-R Instrument
    • T2Candida-R Panel
    • T2Bacteria-R Panel
    • T2Resistance-R Panel
    • The T2MR Technology
  • TEMPUS
  • THERMO FISHER SCIENTIFIC
    • Immunoassays
    • Microbiology
    • Blood Culture